ಸ್ತನ ಕ್ಯಾನ್ಸರ್
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ trial ಗಾಗಿ ಭಾರತದಾದ್ಯಂತ 10 ಆಸ್ಪತ್ರೆಗಳು ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿವೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
ಪ್ರಾಯೋಜಕರು: ಫೈಜರ್
ClinicalTrials.gov ನಲ್ಲಿ NCT07062965
ನೋಂದಣಿಯಲ್ಲಿ ಕೊನೆಯದಾಗಿ 19 ಅಕ್ಟೋಬರ್ 2026 ರಂದು ಅಪ್ಡೇಟ್ ಆಗಿದೆ · ನಾವು 20 ಅಕ್ಟೋಬರ್ 2026 ರಂದು ಓದಿದ್ದೇವೆ